title: Evidence-based coverage decisions? Primum non nocere.
abstract: Drug class reviews are blunt tools for medical decision making. The practice of evidence-based medicine is far more than simply systematic reviews: The patient and doctor are integral. Here we highlight areas of evidence-based coverage decision making where greater balance and transparency could serve to improve the current process, and we recommend elements of a more positive approach that could optimize patient outcomes under resource constraints.
authors.affiliation: Pfizer Inc., New York City, USA. Newell.McElwee@pfizer.com
authors.forename: Newell E
authors.initials: NE
authors.lastname: McElwee
authors.forename: S Yin
authors.initials: SY
authors.lastname: Ho
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: McGuigan
authors.forename: Mark L
authors.initials: ML
authors.lastname: Horn
mesh_terms: D003362:Cost-Benefit Analysis; D003657:Decision Making; D017723:Drug Utilization Review / Q000191:economics / Q000379:methods*; D017598:Efficiency, Organizational; D019317:Evidence-Based Medicine; D005569:Formularies as Topic; D006265:Health Care Coalitions; D006801:Humans; D007356:Insurance, Pharmaceutical Services